{'fraction_non_alphanumeric': 0.014492753623188406, 'fraction_numerical': 0.003780718336483932, 'mean_word_length': 5.616666666666666, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[First experience with "SUPERA Veritas" stent in treatment of patients with occlusive and stenotic lesions of the femoropopliteal arterial segment].

Surgical interventions are used more often for treatment of patients with lesions of arteries of the femoropopliteal segment. Considerable role in widening indications for using an endovascular method of treatment is played by improvement of roentgenosurgical tools and equipment. Implantation of stents into arteries of this segment has become a standard intervention whose results are the starting point for comparing with the results of other methods of roentgenendovascular revascularization. The SUPERA Veritas system is the first nitinol interwoven stent that is fracture-resistant due to special manufacturing technology. The results of multicenter randomized studies are suggestive of its good clinical effect in restoration of the lumen of arteries of the femoral-popliteal segment. According to the findings of European and American researchers, the stent's primary patency lies within the range from 79.2 to 87.7% which is comparable to primary patency of nitinol stents with antiproliferative drug coating. The authors share the first experience with this stent in Russia, reflecting peculiarities of its implantation, as well as describing clinical case reports of using this stent in arteries of the femoropopliteal segment in patients with atherosclerosis of lower limb arteries and diabetes mellitus, also providing the data on stent's patency one year after implantation according to the findings of noninvasive studies.